Savient Pharmaceuticals (SVNT -12.6%) shares plunge after Dendreon (DNDN +4.6%) swipes its CEO,...


Savient Pharmaceuticals (SVNT -12.6%) shares plunge after Dendreon (DNDN +4.6%) swipes its CEO, as John Johnson will take the helm at DNDN on June 30 after only one year at SVNT. Deutsche Bank says Johnson has a history of M&A and his fresh perspective might benefit DNDN's near-term strategy, noting his success in selling Imclone to Eli Lilly and attempts to sell SVNT.
From other sites
Comments (1)
  • shakazoid
    , contributor
    Comments (246) | Send Message
     
    anyone notice this statement in form 8-k filed with SEC (http://bit.ly/AEtyIq) "If such termination by the Company without Cause or resignation by Mr. Johnson with Good Reason occurs within three months before, or twenty-four months after, a Change of Control of the Company (as defined in the Agreement), then Mr. Johnson will be entitled to the sum of 250% of his then current base salary plus 250% of his target annual bonus for such year." Does this mean a possibility of an acquisition in 3 months
    3 Feb 2012, 12:32 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs